Skip to main content
Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
84.90
+2.30 (2.78%)
Apr 29, 2026, 4:08 PM HKT

Innovent Biologics Revenue

In the year 2025, Innovent Biologics had annual revenue of 13.04B CNY with 38.42% growth. Innovent Biologics had revenue of 7.09B in the half year ending December 31, 2025, with 102.26% growth.

Revenue
13.04B CNY
Revenue Growth
+38.42%
P/S Ratio
9.88
Revenue / Employee
1.74M CNY
Employees
7,502
Market Cap
143.33B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202513.04B3.62B38.42%
Dec 31, 20249.42B3.22B51.82%
Dec 31, 20236.21B1.65B36.21%
Dec 31, 20224.56B286.65M6.71%
Dec 31, 20214.27B425.91M11.08%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
WuXi Biologics 24.25B
Akeso 3.40B
Sichuan Kelun-Biotech Biopharmaceutical 2.29B
Sino Biopharmaceutical 35.43B
BeOne Medicines AG 41.59B
RemeGen 3.62B
3SBio 19.69B
Biocytogen Pharmaceuticals (Beijing) 1.53B
Revenue Rankings

Innovent Biologics News

More News